BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12576466)

  • 1. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
    Henry CJ; McCaw DL; Turnquist SE; Tyler JW; Bravo L; Sheafor S; Straw RC; Dernell WS; Madewell BR; Jorgensen L; Scott MA; Higginbotham ML; Chun R
    Clin Cancer Res; 2003 Feb; 9(2):906-11. PubMed ID: 12576466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder.
    Greene SN; Lucroy MD; Greenberg CB; Bonney PL; Knapp DW
    J Am Vet Med Assoc; 2007 Oct; 231(7):1056-60. PubMed ID: 17916030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
    Upton ML; Tangner CH; Payton ME
    J Am Vet Med Assoc; 2006 Feb; 228(4):549-52. PubMed ID: 16478428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.
    Knapp DW; Glickman NW; Widmer WR; DeNicola DB; Adams LG; Kuczek T; Bonney PL; DeGortari AE; Han C; Glickman LT
    Cancer Chemother Pharmacol; 2000; 46(3):221-6. PubMed ID: 11021739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study.
    Poirier VJ; Forrest LJ; Adams WM; Vail DM
    J Am Anim Hosp Assoc; 2004; 40(2):131-6. PubMed ID: 15007049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993).
    Chun R; Knapp DW; Widmer WR; Glickman NW; DeNicola DB; Bonney PL
    J Am Vet Med Assoc; 1996 Nov; 209(9):1588-91. PubMed ID: 8899023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective evaluation of doxorubicin-piroxicam combination for the treatment of transitional cell carcinoma in dogs.
    Robat C; Burton J; Thamm D; Vail D
    J Small Anim Pract; 2013 Feb; 54(2):67-74. PubMed ID: 23286739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder.
    Boria PA; Glickman NW; Schmidt BR; Widmer WR; Mutsaers AJ; Adams LG; Snyder PW; DiBernardi L; de Gortari AE; Bonney PL; Knapp DW
    Vet Comp Oncol; 2005 Jun; 3(2):73-80. PubMed ID: 19379215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy.
    Mutsaers AJ; Mohammed SI; DeNicola DB; Snyder PW; Glickman NW; Bennett PF; de Gortari AE; Bonney PL; Knapp DW
    Prostaglandins Leukot Essent Fatty Acids; 2005 Mar; 72(3):181-6. PubMed ID: 15664302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
    Mohammed SI; Bennett PF; Craig BA; Glickman NW; Mutsaers AJ; Snyder PW; Widmer WR; DeGortari AE; Bonney PL; Knapp DW
    Cancer Res; 2002 Jan; 62(2):356-8. PubMed ID: 11809678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.
    Allstadt SD; Rodriguez CO; Boostrom B; Rebhun RB; Skorupski KA
    J Vet Intern Med; 2015 Jan; 29(1):261-7. PubMed ID: 25619518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
    Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
    Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
    Mohammed SI; Craig BA; Mutsaers AJ; Glickman NW; Snyder PW; deGortari AE; Schlittler DL; Coffman KT; Bonney PL; Knapp DW
    Mol Cancer Ther; 2003 Feb; 2(2):183-8. PubMed ID: 12589035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.
    Marvel SJ; Séguin B; Dailey DD; Thamm DH
    Vet Comp Oncol; 2017 Dec; 15(4):1417-1427. PubMed ID: 28217972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
    Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
    Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-II combined intra-arterial chemotherapy for locally advanced bladder cancer: a case series study at a single institution.
    Shimabukuro T; Nakamura K; Uchiyama K; Tei Y; Aoki A; Naito K
    Hinyokika Kiyo; 2006 Feb; 52(2):99-105. PubMed ID: 16541762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical signs, treatments, and outcome in cats with transitional cell carcinoma of the urinary bladder: 20 cases (1990-2004).
    Wilson HM; Chun R; Larson VS; Kurzman ID; Vail DM
    J Am Vet Med Assoc; 2007 Jul; 231(1):101-6. PubMed ID: 17605672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.